Wednesday, October 14, 2009
APQ: U.S. Pharmaceutical Company Executive
It’s a matter of perspective, but for pharmaceutical companies, patients continue to be the primary focus, because successfully impacting patient outcomes is the objective of pharmaceutical research and development. Physicians, of course, are central to successful patient care and, as such, have been – and will continue to be – important stakeholders moving forward. 
Filed under: Doctors, Drugs, Panel Point of View
by
admin
at 6:50 pm 10.14.09
Keywords: no tag
Thursday, September 24, 2009
APQ: U.S. Pharmaceutical Company Executive
The current trend seems to be that physicians will have less control overall and perhaps will have less earning power, but I still think they will serve a very important role and we should not lose sight of them as important customers.
Filed under: Panel Point of View
by
admin
at 8:01 pm 09.24.09
Keywords: no tag
Thursday, September 24, 2009
APQ: Executive – Large Healthcare Provider
Physicians will continue to be stakeholders in healthcare. However, with the continuing shortage of primary care physicians and the increase in numbers of nurse practitioners, nurse anesthetists and other medical professionals, doctors will find themselves relinquishing some of the influence that they currently have.
Filed under: Panel Point of View
by
admin
at 8:00 pm 09.24.09
Keywords: no tag
Wednesday, September 23, 2009
APQ: Paul Oestreicher, Ph.D., President, Oestreicher Communications, LLC and Adjunct Professor, NYU School of Continuing and Professional Studies
Assuming some version of healthcare reform legislation makes it out of the Congress, physicians will remain a key stakeholder. Yet, we’re bound to see a further flattening of influence. Why? Physicians, for the most part, will continue to do their jobs well. So, aside from making us a healthier nation, and
Filed under: Panel Point of View
by
admin
at 7:20 pm 09.23.09
Keywords: no tag
